A5054444597- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Viral-associated cancers and disorders
- Cell death mechanisms and regulation
- Acute Myeloid Leukemia Research
- Nausea and vomiting management
- Immunodeficiency and Autoimmune Disorders
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- Circular RNAs in diseases
- Cancer Mechanisms and Therapy
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Bone health and treatments
- Cancer therapeutics and mechanisms
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Galectins and Cancer Biology
- Hematological disorders and diagnostics
- Lung Cancer Treatments and Mutations
- Genomic variations and chromosomal abnormalities
- Advanced Breast Cancer Therapies
Institute of Hematology & Blood Diseases Hospital
2014-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2010-2024
Guangdong Pharmaceutical University
2022-2024
Campo Arqueologico de Mertola
2021
Academy of Medical Sciences
2019-2020
Affiliated Zhongshan Hospital of Dalian University
2007
For classical Hodgkin lymphoma (cHL), programmed death-l (PD-1) is a well-recognized attractive target. This multicenter, single-arm, phase II study evaluated the efficacy and safety of camrelizumab, humanized high-affinity IgG4 mAb against PD-1, in Chinese patients with relapsed or refractory cHL.Patients who had failed to achieve remission experienced progression after autologous stem cell transplantation received at least two lines systemic chemotherapies were given camrelizumab 200 mg...
Circularly permuted TRAIL (CPT), a recombinant mutant of human Apo2L/TRAIL, is novel antitumor candidate for multiple myeloma (MM) and other hematologic malignancies. In this phase II study, the safety efficacy CPT plus thalidomide was investigated in thalidomide-resistant MM patients. A total 43 patients were recruited into three cohorts based on dosage sequence: 5 mg/kg (n = 11), 8 17), 10 15). administered via intravenous infusion days 1-5, given orally at 100 mg once daily each 21-day...
MicroRNA-223 (miR-223) expression has been demonstrated to be stage-specific in B cell differentiation and associated with the outcome of chronic lymphocytic leukemia (CLL). However, pattern miR-223 lymphoproliferative disorders its association Chinese patients CLL have not investigated. In this study, we that was significantly decreased CLL, mantle lymphoma (MCL) splenic marginal zone (SMZL). progression from early advanced clinical stages lower elevated β(2)-microglobulin, unmutated...
Despite the recent development of new therapies, multiple myeloma (MM) remains an incurable disease. Thus, new, effective treatments are urgently needed, particularly for relapsed or refractory MM (RRMM). In earlier phase I study, a novel form recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that is currently in clinical treatment hematologic malignancies, i.e., circularly permuted TRAIL (CPT), was well tolerated at dose 2.5 mg/kg per day and showed...
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains an effective treatment for non-Hodgkin lymphoma (NHL). The limited availability of carmustine has prompted the exploration novel alternative conditioning regimens. This study aimed to compare efficacy and safety profile GBM/GBC (gemcitabine, busulfan, melphalan or cyclophosphamide) compared with standard BEAM/BEAC regimens (carmustine, etoposide, cytarabine, ASCT in patients NHL.
Chromosome 1q21 aberrations in multiple myeloma have attracted much attention for a long time, however, the prognostic value is still under investigation. We confirmed independent impact of this non-randomized clinical study. Our study noted that additional copies and larger clonal size gain did not worsen outcome. discovered was associated with acquisition new chromosome abnormalities genomic instability, evidenced by strong correlation between complex karyotypes or more than two...
The serum free light chain (sFlc) levels were measured for 122 Chinese patients with newly diagnosed symptomatic multiple myeloma (NDSMM), and κ/λ ratios (rFlc) calculated. data analyzed the roles of sFlc rFlc in diagnosis prognosis MM. Abnormal and/or detected 99.2% patients, demonstrating that FLC assay is much more sensitive than commonly used methods. Baseline successfully predicted overall survival (OS). median OS was not reached (NR) versus 23 months low sFLC group (sFLC-κ < 180 mg/L...
Objectives: Circularly permuted tumor necrosis factor-related apoptosis-inducing ligand (CPT), or CPT, is a novel antitumor drug candidate. This phase 1b study evaluated the safety, tolerability, pharmacokinetics (PK), and efficacy of single-agent CPT in patients with relapsed refractory multiple myeloma (RRMM), aimed to identify recommended dose for 2 study. Materials Methods: Patients received single doses (once daily 5 consecutive days per 21-d cycle) intravenous infusion at 5, 6.5, 8,...
Aberrant expression of microRNAs in chronic lymphocytic leukemia (CLL) has been reported to be associated with clinical outcome and improve prognostic stratification. The aim this study was explore the association miR-29c parameters survival 53 Chinese patients CLL. We showed that level decreased significantly from early advanced stages, lower β(2)-microglobulin higher than 3.5 mg/L or disease progression death. With cut-off determined by receiver operating characteristic (ROC) curve...
Recently, a gene named TOSO was identified as being overexpressed and associated with the anti-apoptotic characteristic of chronic lymphocytic leukemia (CLL). However, association expression clinical features CLL has not been fully described, especially in Chinese patients. detected by quantitative RT-PCR CD19+ sorted cells cohort 81 untreated patients CLL. The results showed that significantly higher than healthy controls (p = 0.027) other B-cell lymphoproliferative diseases 0.033). level...
Background: Peripheral T cell lymphomas (PTCL) have been demonstrated to a poorer prognosis than diffuse large B lymphoma (DLBCL) due high frequency of bone marrow involvement (BMI). However, the clinical characteristics PTCL with BMI not fully described, and outcomes DLBCL well compared. Methods: The survival 25 nodal cases 42 were Results: Most patients had lymphadenopathy (88%), symptoms (76%), an elevated LDH level (68%), anemia (64%), splenomegaly (60%), poor performance status (52%)....